Mupirocin Infectopharm (Mupirocin)

Mupirocin inhibits bacterial isoleucyl‑tRNA synthetase, an enzyme essential for protein synthesis. By blocking this step, the drug prevents bacteria from producing proteins needed for growth, resulting in a bacteriostatic effect at low concentrations and a bactericidal effect at higher concentrations against Gram‑positive organisms.

The prescribed dose is determined by the treating clinician. Typically, a thin layer of the ointment is applied to the affected area two to three times daily, but the exact regimen, duration, and amount should follow the prescriber’s instructions.

Safety data for mupirocin in pregnancy and lactation are limited. It should only be used when the potential benefit justifies any possible risk to the fetus or infant. Healthcare providers should evaluate each case individually and discuss potential risks with the patient.

To place an order, submit an enquiry on the product page at gnhindia.com, specifying the required quantity. GNH India supplies hospitals, pharmacies and procurement teams worldwide. After submission, the sales team will verify trade or institutional credentials and respond with pricing, availability, shipping details (including any cold‑chain requirements) and necessary import documentation.

Mupirocin offers a broad spectrum against Gram‑positive bacteria, including methicillin‑resistant Staphylococcus aureus (MRSA), which many alternatives such as fusidic acid may not cover. Its unique mechanism of inhibiting isoleucyl‑tRNA synthetase provides a low risk of cross‑resistance, making it a preferred choice for resistant skin infections.

Store the ointment at temperatures below 25 °C. Keep it in the original container, protect it from moisture and direct sunlight, and ensure the cap is tightly closed when not in use. Do not freeze the product.

The ointment is applied topically to clean, dry skin. Gently spread a thin layer over the affected area, usually two to three times daily, unless directed otherwise. Avoid contact with eyes, mucous membranes, and large open wounds unless specifically instructed by a healthcare professional.

Serious adverse reactions, though rare, include allergic contact dermatitis, severe skin necrosis, systemic hypersensitivity, and, in extreme cases, Stevens‑Johnson syndrome or anaphylaxis. Patients should discontinue use and seek immediate medical attention if they experience widespread rash, swelling, or difficulty breathing.

Individuals with a known hypersensitivity to mupirocin, other topical antibiotics, or any component of the formulation should avoid its use. It is also contraindicated on extensive, deep, or severely damaged skin where systemic absorption could be increased, and in patients with a history of severe allergic reactions to similar agents.